Search Results
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
Mabwell based on its ADC development platform. It is the world's first Nectin-4 ADC to enter Phase III clinical trials for cervical cancer (CC) and triple-negative breast cancer (TNBC). Four pivotal Phase III clinical studies are underway. 9MW2821 has obtained FDA Fast Track Designation for three indications,
More news about: Mabwell
Jun 18, 2026, 10:19 ET CPSC Posts Product Recalls and Product Safety Warnings to its Web Site
Arizer Solo III Portable Vaporizers Recalled Due to Fire and Burn Hazards; Risk of Serious Injury or Death; Imported by 7111495 Canada | CPSC.govUnits:
More news about: U.S. Consumer Product Safety Commission
Jun 18, 2026, 10:07 ET GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
(NASDAQ: GRAL) told investors its over 140,000-participant NHS-Galleri trial was designed to achieve a statistically significant reduction in Stage III and IV cancers. On February 19, 2026, the company disclosed the opposite: the primary endpoint "was not observed." GRAL shares collapsed 50.55% in a
More news about: SueWallSt.com
Jun 18, 2026, 10:01 ET Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The drug is administered via a convenient subcutaneous route and is currently undergoing Phase III clinical evaluation for the treatment of CIDP.Immunovant's Batoclimab is a human monoclonal antibody targeting the neonatal Fc receptor
More news about: DelveInsight Business Research, LLP
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
information about joining the class action] On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
action]On March 13, 2026, Immutep issued a press release "announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers - NNOX
demand for its products; (ii) in reality, Nano-X's production and manufacturing operations were poorly aligned with demand for the Company's products; (iii) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (iv) the foregoing significantly increased the likelihood
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against BitGo Holdings, Inc. and Certain Officers - BTGO
Defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Lucid Group, Inc. and Certain Officers - LCID
deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company's business and financial results; (iii) accordingly, the Defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against AeroVironment, Inc. and Certain Officers - AVAV
U.S. Space Force's ongoing efforts to modernize the SCN; (ii) accordingly, Defendants overstated AeroVironment's business and financial prospects; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.On January 20, 2026, AeroVironment announced
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Graphic Packaging Holding Company and Certain Former Officers - GPK
and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing
More news about: Pomerantz LLP
Jun 18, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against ServBanc Holdco, Inc., ServBank, National Association, IF Bancorp, Inc., and its Board of Directors - IROQ
and Special Dividend were misleading insofar as they overstated the likelihood that IF Bancorp shareholders would receive the Special Dividend; and (iii) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable
More news about: Pomerantz LLP
Jun 18, 2026, 09:15 ET Lion Group Holding Ltd. Signs Non-Binding Memorandum of Understanding to Acquire Aquila Hash, Inc.
that offers a wide spectrum of products and services, including (i) total return swap (TRS) trading, (ii) contract-for-difference (CFD) trading, and (iii) Over-the-counter (OTC) stock options trading. Additional information may be found at http://ir.liongrouphl.com.About
More news about: Lion Group Holding Ltd.
Jun 18, 2026, 09:05 ET Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line
automated manufacturing line; (ii) the Company's plans and expectations regarding international commercialization through joint venture partnerships; and (iii) the expected capabilities of the Co-Dx platform, including AI and outbreak surveillance functionality. Such statements are subject to a number of risks
More news about: Co-Diagnostics
Jun 18, 2026, 09:00 ET YY Group Holding Limited Announces Effective Date of 30-for-1 Reverse Stock Split
the hospitality market across Southeast Asia, Hong Kong, and other markets in which the Company operates, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, (vi) our ability to successfully
More news about: YY Group Holding Limited
Jun 18, 2026, 08:00 ET RedHill Biopharma Announces Up To $19.4 Million Private Placement
nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase
More news about: RedHill Biopharma Ltd.
Jun 18, 2026, 07:32 ET IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
the Company is (i) in a situation of serious financial difficulty; (ii) the Transaction is designed to improve the financial position of the Company; (iii) the circumstances described in Section 5.5(f) of MI 61-101 are not applicable; (iv) the Board, acting in good faith, and the Special Committee, which
More news about: IM Cannabis Corp.
Jun 18, 2026, 07:32 ET IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
the Company is (i) in a situation of serious financial difficulty; (ii) the Transaction is designed to improve the financial position of the Company; (iii) the circumstances described in Section 5.5(f) of MI 61-101 are not applicable; (iv) the Board, acting in good faith, and the Special Committee, which
More news about: IM Cannabis Corp.
Jun 18, 2026, 04:00 ET Quantum Communication Fieldlab Rotterdam moves quantum-secure communication from pilot to operational use
QUEST project, focused on enabling Quantum Key Distribution across two Eurofiber data centres in the Randstad, is supported through Kansen voor West III and co-financed by the European Regional Development Fund and the Province of Zuid-Holland. QCFR complements that line of development by providing a
More news about: INSPIR8ION
Jun 18, 2026, 00:57 ET WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.WuXi Biologics regards
More news about: WuXi Biologics
Jun 17, 2026, 19:28 ET QS World University Rankings 2027
301Universidad Carlos III de Madrid (UC3M)364
More news about: QS Quacquarelli Symonds
Jun 17, 2026, 18:42 ET FIBRA Prologis Anuncia Cambios a su Comité Técnico
situación económica internacional regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Jun 17, 2026, 18:37 ET FIBRA Prologis Anuncia Cambios a su Comité Técnico
situación económica internacional regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Jun 17, 2026, 17:41 ET FIBRA Prologis Announces Changes to its Technical Committee
national, international, regional and local economic climates, (ii) changes in financial markets, interest rates and foreign currency exchange rates, (iii) increased or unanticipated competition for our properties, (iv) risks associated with acquisitions, dispositions and development of properties, (v)
More news about: FIBRA Prologis